Chubb Ltd
$ 328.14
0.38%
12 Jun - close price
- Market Cap 127,272,419,000 USD
- Current Price $ 328.14
- High / Low $ 328.64 / 319.71
- Stock P/E 11.60
- Book Value 189.93
- EPS 28.29
- Next Earning Report 2026-07-28
- Dividend Per Share $3.88
- Dividend Yield 1.19 %
- Next Dividend Date 2026-07-02
- ROA 0.03 %
- ROE 0.15 %
- 52 Week High 343.58
- 52 Week Low 260.77
About
Chubb Limited, incorporated in Zurich, Switzerland, is the parent company of Chubb, a global provider of insurance products covering property and casualty, accident and health, reinsurance, and life insurance and the largest publicly traded property and casualty company in the world.
Analyst Target Price
$345.04
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-21 | 2026-02-03 | 2025-10-21 | 2025-07-22 | 2025-04-22 | 2025-01-28 | 2024-10-29 | 2024-07-23 | 2024-04-23 | 2024-01-30 | 2023-10-24 | 2023-07-25 |
| Reported EPS | 6.82 | 7.52 | 7.49 | 6.14 | 3.68 | 6.02 | 5.72 | 5.38 | 5.41 | 5.54 | 4.95 | 4.92 |
| Estimated EPS | 6.61 | 6.78 | 6.16 | 5.97 | 3.23 | 5.45 | 4.99 | 5.15 | 5.3 | 5.12 | 4.42 | 4.42 |
| Surprise | 0.21 | 0.74 | 1.33 | 0.17 | 0.45 | 0.57 | 0.73 | 0.23 | 0.11 | 0.42 | 0.53 | 0.5 |
| Surprise Percentage | 3.177% | 10.9145% | 21.5909% | 2.8476% | 13.9319% | 10.4587% | 14.6293% | 4.466% | 2.0755% | 8.2031% | 11.991% | 11.3122% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-28 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 6.56 |
| Currency | USD |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-02 | 2026-04-06 | 2026-01-02 | 2025-10-03 | 2025-07-03 | 2025-04-04 | 2025-01-03 | 2024-10-04 | 2024-07-05 | 2024-04-05 |
| Amount | $1.02 | $0.97 | $0.97 | $0.97 | $0.97 | $0.91 | $0.91 | $0.91 | $0.91 | $0.86 |
Next Dividend Records
| Dividend per share (year): | $3.88 |
| Dividend Yield | 1.19% |
| Next Dividend Date | 2026-07-02 |
| Ex-Dividend Date | 2026-06-12 |
Recent News: CB
2026-06-14 19:31:03
JPMorgan reiterated an Overweight rating on Lumentum (LITE) and maintained its price target, easing investor concerns about co-packaged optics adoption, essential for AI data centers. The company reported strong fiscal third-quarter 2026 results with significant revenue and earnings growth, driven by laser chips and scale-across components. Lumentum, an optical and photonic technology company, is positioned as a key player in AI infrastructure and data center connectivity.
2026-06-14 11:21:08
Wolfe Research has significantly raised its price target for Micron Technology (MU) stock from $550 to $1,250, maintaining an "Outperform" rating. The firm's revised memory model anticipates increases in DRAM pricing for CY 2026 and CY 2027, projecting Micron's revenue to reach $226.5 billion and EPS to hit $135 for 2027. This optimistic outlook is driven by expected demand surpassing supply through at least 2027, with long-term agreements being secured between suppliers and major customers.
2026-06-14 05:46:10
Bernstein analyst Lee Hambright lowered Medtronic plc (NYSE:MDT)'s price target from $112 to $97, while maintaining an 'Outperform' rating. This adjustment comes despite Medtronic exceeding Q4 2026 expectations in profits and revenue, driven by strong growth in its Cardiac Ablation Solutions. However, the company's projected adjusted annual profit for FY 2027 is below analyst expectations, and Bernstein seeks stronger EPS growth from Medtronic.
2026-06-14 05:38:25
RBC Capital analyst Trung Huynh upgraded Pfizer (NYSE: PFE) from ‘Underperform’ to ‘Sector Perform’ with a $25 price target, despite an unchanged overall investment outlook. The upgrade is attributed to the stock's recent 8% drop, making its 9-times forward earnings valuation more attractive, and its robust 6.57% dividend yield which is seen as a downside mitigator. Upcoming catalysts include Sigvotatug vedotin in lung cancer and mevro later this year, alongside strong Q1 fundamentals that could lead to a 2026 guidance upgrade.
2026-06-13 02:37:11
Barclays has reiterated its 'Hold' rating on Chubb Ltd (CB.US) while adjusting its price target downwards from $374 to $368. This minor change reflects a continued neutral outlook on the company's stock by the analyst.
2026-06-12 18:51:13
Cincinnati Financial's stock is experiencing quiet trading on the NYSE, shifting market focus to its valuation and fundamental strengths, rather than headline-driven movements. The article delves into the company's business model, underwriting performance, investment income, and capital strength as key drivers of its valuation, especially in comparison to its industry peers. It also highlights the significance of its dividend policy and the influence of macroeconomic factors like interest rates and inflation on investor sentiment during this consolidation phase.
